Abstract
Introduction
Of the Ϸ1.5 million patients diagnosed with cancer in the United States annually, the vast majority receive radiation therapy at some point in the course of treatment. More specifically, radiation has proved central to treating both primary and metastatic brain tumours, in particular offering the most effective non-surgical therapy for malignant gliomas, including Glioblastoma multiforme (GBM) [1] . Normal [2] [3] [4] [5] [6] . Met activation plays an important physiologic role in a diverse range of processes including embryogenesis and tissue regeneration [7, 8] ; however, aberrant Met signalling has long been associated with the pathogenesis and pathophysiology of a wide variety of human malignancies [9] [10] [11] . Activated Met signalling results in a complex genetic program collectively referred to as 'invasive growth' [12] mediated by multiple downstream pathways including increased cell survival, proliferation, motility/migration, invasion and angiogenesis [9] .
Met protein expression is typically up-regulated in human gliomas, with the degree of up-regulation correlating with tumour grade; further, Met signalling often becomes up-regulated in the context of an autocrine loop [13] [14] [15] .
In addition to influencing tumour biology, the Met pathway has been implicated as a determinant of glioma cell response to ionizing radiation (IR). Two previously reported studies have shown that delivery of ribozymes or antisense gene constructs targeting HGF and/or Met gene expression enhances the radiosensitivity of glioma cell lines in vitro and in vivo. In both cases greater than additive responses to drug plus IR therapy were realized, resulting in decreased cell proliferation and tumour volumes, as well as increased tumour-free survival.
However, these studies were limited insofar as they required direct, local injection of agents and adjuvant reagents that currently have no clinical precedent [16, 17] [18, 19] . Previous studies have shown, either as a mono-or combination therapy, the ability of AMG102 to inhibit growth of tumours, including gliomas, both in vitro and in vivo [18, [20] [21] [22] [27, 28] 
Materials and methods

Cell lines and treatment
. Integrity of this checkpoint was investigated by distinguishing G2-versus M-phase cells in the 4N cell population following IR. U-87 MG cells were pre-treated with AMG102 (1 g/ml), exposed to 2 Gy, and stained for the phospho-H3 histone as an M-phase marker [23]. The addition of drug treatment did not alter the mitotic index of cells, as compared with their control or IR-only counterparts (data not shown). In particular, the low mitotic index seen in combination treated cells mirrored that of IR-only cells, indicating an intact G2 checkpoint. Taken together, these data indicate that AMG102-induced radiosensitization does not result from cell cycle redistribution, nor is it a result of G2-checkpoint abrogation.
To define the mode of cell death contributing to the dose enhancement detected by the clonogenic survival assay, U-87 MG cells pre-treated with AMG102 (1 g/ml) for 24 hrs and exposed to 2 Gy were analysed for both apoptosis and mitotic catastrophe.
AMG102 exposure alone had no effect on the level of U-87 MG apoptosis. When combined with radiation, a slight increase in apoptotic index at 24 and 72 hrs after IR was detected in AMG102 treated cells, which was not statistically significant (Fig. 3A). For solid tumour cells the most frequent mode of radiation-induced death is mitotic catastrophe [29]. Cells undergoing mitotic catastrophe are detectable at 48 and 72 hrs after irradiation with 2 Gy. AMG102 exposure alone did not induce U-87 MG mitotic catastrophe. However, irradiation of AMG102 treated cells resulted in a significant increase in cells undergoing mitotic catastrophe at 48 and 72 hrs after IR as compared with cells that received radiation alone (Fig. 3B). The AMG102-mediated increase in radiation-induced mitotic catastrophe suggests that inhibition of Met activation modifies the induction and/or the repair of radiation-induced DNA damage. The formation of DNA double strand breaks (DSB) following exposure to IR is central to the cytotoxicity associated with radiation therapy [30]. The measurement of the phospho-histone 2AX (␥H2AX) nuclear foci has been established as a sensitive indicator of radiation-induced DSBs, as well as a reliable predictor of cell killing when defined at 24 hrs following radiation exposure [31-33]. To quantitate nuclear ␥H2AX foci, immunofluorescence staining of U-87 MG cells pre-treated for 24 hrs with AMG102
(1 g/ml) followed by 2 Gy was performed (Fig. 4A ). AMG102 treatment alone had no effect on the number of ␥H2AX foci. At 1 hr after IR there was no difference in the number of foci in drug treated and control groups, suggesting that AMG102 has no effect on the initial level of radiation-induced DSBs. However, at 6 and 24 hrs after IR there was a significantly greater number of ␥H2AX foci in the drug treated groups. These data suggest that treatment with AMG102 inhibits the repair of IR-induced DNA DSBs.
To further investigate the effects of AMG102 on radiationinduced DSBs and their repair we performed the neutral comet assay (Fig. 4B) [34] . U-87 MG cells were exposed to AMG102 (1 g/ml) for 24 hrs, irradiated with 10 Gy to induce sufficient
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No claim to original US government works. [12, 38] . Many of these effectors have been shown to have roles in the cellular radiation response [39] [40] [41] . It has also been noted that clinically relevant doses of IR have been shown to activate Met signalling [24, 25, 42] and moreover, activated Met signalling has been directly shown to enhance DNA repair following exposure to IR [43] . The persistence of DNA DSBs is well known to be an important mediator of cytotoxicity following exposure to IR [30] [44, 45] .
Fig. 1 The influence of AMG102 on Met activation in U-
Effector molecules downstream of activated Met are commonly considered to be anti-apoptotic [43] . In previous studies combining Met modulation with IR, studies investigating the use of Met axis modulators as monotherapies [11, 46, 47] , and studies examining AMG102 itself [18, 20] [48] . It is also of note that delivery of similar therapeutics to intracranial tumours has been shown to be possible, thus indicating that the blood-brain and blood-tumour barriers do not block passage of such molecules [46, 49] .
Conclusion
The data presented here indicate the capacity of AMG102, the fully human anti-HGF monoclonal antibody, to radiosensitize U-87 MG GBM cells in vitro and in vivo. We propose the mechanism of radiosensitization involves the inhibition of DNA repair processes downstream of activated Met, leading to increased cell death by mitotic catastrophe.
